乙型肝炎病毒与肝细胞癌的抗病毒治疗与风险评估  

Hepatitis B virus and hepatocellular carcinoma： antiviral therapy and risk estimation

作　　者：王翀[1] 乔安意[1] 

机构地区：[1]广州医学院第三附属医院肝胆外科,广州510150

出　　处：《国际外科学杂志》2012年第12期846-848,共3页International Journal of Surgery

摘　　要：肝细胞癌在全世界的发病率逐年增高，已经成为导致癌症相关死亡的主要疾病之一。多年来研究发现，乙型肝炎病毒的慢性感染是导致肝细胞癌发病的重要原因，针对乙肝的抗病毒治疗可明显降低肝细胞癌的发病牢及术后的肿瘤复发。对乙型肝炎患者做出适当的相关风险评估，给予高危患者及时有效的医疗丁预，对于预防肝细胞癌的发生，延缓其发展有重要作用。The incidence of hepatocellular carcinoma is increasing year by year all over the world. Hepatoma has become one of the main causes of cancer-related death. For many year, studies found the chronic hepatitis B virus infection is the leading cause of hepatocellular carcinoma, and antiviral therapy for hepatitis B virus could obviously reduce the incidence of hepatoma and prevent recurrence after hepateetomy. Making appropriate risk estima- tion in patients with chronic hepatitis B and providing patients with high risk the effective medical intervention can help to prevent the occurrence and delay the development of hepatocellular carcinoma.

关 键 词：肝炎病毒 乙型 癌 肝细胞 抗病毒治疗 风险评估 

分 类 号：R735[医药卫生—肿瘤] R51[医药卫生—临床医学]